Vitrafy Life Sciences (VFY) investor relations material

Executive summary

• Completed Phase II of the U.S. military platelet cryopreservation program with high-quality post-thaw outcomes, operational simplicity, and the largest sample set tested, accelerating commercial engagement in both military and civilian blood networks.

• Built and deployed four Guardian cryopreservation units, with installations in France and the U.S. for demos, commercial engagement, and regulatory objectives.

• Initiated and progressed collaboration with IMV Technologies in France for animal health and reproduction, deploying devices and personnel, with initial bovine semen testing scheduled.

• Strong commercial interest and engagement generated across blood, cell & gene therapy, and animal health markets, with multiple product demonstrations and pipeline development underway.

• Maintained focus on the U.S. market as a primary area, while expanding global partnerships and commercial activities.

Financial highlights

• Ended the quarter with AUD 18.5 million ($18.5m) in cash and term deposits, providing a four-quarter funding runway.

• Net operating cash outflow for the quarter was $4.4m, with an average monthly cash burn of ~$1.8m and cash expenditure increasing to $5.4m.

• Received $0.9m from the Industry Growth Program grant during the quarter, with further grant inflows expected.

• Costs expected to remain flat next quarter, then increase in H2 2026 due to regulatory testing, U.S. team expansion, and device investment.

• Revenue visibility improving, with growth anticipated from IMV, aquaculture, grants, and interest income.

Outlook and guidance

• FDA registration for the Guardion device targeted for H1 FY2027, unlocking access to U.S. regulated human health markets.

• Expects phase II blood platelets data to accelerate commercialization in both military and civilian sectors.

• Plans to scale device supply and manufacturing in the U.S. to meet anticipated demand, with ramp-up planned through H1 FY2027.

• Ongoing expansion in animal reproduction and aquaculture verticals, with further commercial agreements and revenue targeted.

• Anticipates increased cash costs in H2 2026, offset by grant inflows and rising service revenues.